Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR fluorescence imaging agent ABY-029

A fluorescence imaging and contrast agent composed of an epidermal growth factor receptor (EGFR)-targeting affibody tracer molecule and labeled, through maleimide, with a near-infrared (NIR) fluorescent probe, IRDye 800CW, with potential use in the imaging of EGFR-overexpressing cells. Upon administration, ABY-029 targets and binds to EGFR-overexpressing tumor cells. Upon fluorescent imaging, the fluorescent dye can be visualized and EGFR-positive tumor cells can be detected.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	ABY-029 trifluoroacetate salt fluorescently-labeled Anti-EGFR affibody molecule ABY-029 IRDye 800CW maleimide-labeled affibody peptide
Code name:	ABY-029

anti-EGFR fluorescence imaging agent ABY-029

Search NCI's Drug Dictionary